PRT1419 + Azacitidine + Venetoclax
Phase 1Terminated 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia
Conditions
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
Trial Timeline
Mar 22, 2022 → Jan 19, 2024
NCT ID
NCT05107856About PRT1419 + Azacitidine + Venetoclax
PRT1419 + Azacitidine + Venetoclax is a phase 1 stage product being developed by Prelude Therapeutics for Acute Myeloid Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT05107856. Target conditions include Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05107856 | Phase 1 | Terminated |
Competing Products
20 competing products in Acute Myeloid Leukemia